Proactive Investors - Run By Investors For Investors

Orthocell completes CelGro study accelerating dental implant treatments

The positive data comes as Orthocell is active in partnering discussions and will support the company to gain traction in key markets.
Orthocell completes CelGro study accelerating dental implant treatments
CelGro continues to gain traction in Europe with strategic partnering activities ongoing

Orthocell Ltd (ASX:OCC) has completed the CelGro® single-stage dental implant study designed to assess effectiveness and predictability in accelerating treatment timeframes.

The marketing study follows the successful two-stage dental implant trial and market authorisation of CelGro in the European Union for dental bone and soft tissue applications.

Study results further validate CelGro as a superior medical device for bone and soft tissue repair and will assist in driving market adoption.

“CelGro as the best in class collagen membrane”

Orthocell’s managing director Paul Anderson said: “CelGro’s ability to deliver superior bone growth has the potential to revolutionise dental implant techniques and is highly desired by physicians and potential partners.

“The latest results provide further evidence that positions CelGro as the best in class collagen membrane.”

The 10 patients treated in the marketing study had previously suffered, in some cases for many years, from damaged, missing or diseased teeth.

Symptoms prior to treatment included severe irritation, bleeding gums, an inability to chew or eat certain foods and enjoy a normal diet.

Treatment completion in four months

After surgery with CelGro the impact on patients’ lives was ‘significant’ with patients having successfully generated enough new bone to stabilise their implants and complete treatment in about four months.

This is almost half the time of the usual two-stage dental implant treatment.

The performance study underpins the compatibility and versality of CelGro as a platform technology and highlights the potential to extend the company’s innovative dental product range.

Orthocell is also leveraging the EU regulatory approval and finalising its submission for US regulatory clearance.


View full OCC profile View Profile

Orthocell Ltd Timeline

December 05 2016

Related Articles

human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
scientist in laboratory
May 24 2019
Here we take a closer look at healthcare investor NetScientific PLC (LON:NSCI)

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use